Available antipsychotic treatments work by blocking dopamine receptors. The new drug, Cobenfy, takes a different approach.
The U.S. Food and Drug Administration has approved a new drug for adults with schizophrenia,  the FDA announced Thursday.
The medication is the first in decades to have a different mode of action than do current drugs, achieving better symptom ...
Bristol Myers Squibb's drug, KarXT, improved symptoms of adults with schizophrenia and had fewer side effects than ...
The approval comes less than a year Bristol Myers Squibb paid $14 billion to acquire the developer of the drug, Karuna ...
This drug takes the first new approach to schizophrenia treatment in decades," Farchione continued. "This approval offers a ...
Cobenfy was approved to reduce the psychotic symptoms associated with schizophrenia. It is a new type of medicine that works ...
In testing, Cobenfy eased schizophrenia symptoms without some of the disruptive side effects typical of existing drugs. The results have been met with excitement, as well as caution.
The Food and Drug Administration, as expected, approved KarXT, the first new type of drug for schizophrenia in decades. It appears to be effective, but its main advantage is milder side effects.
The Food and Drug Administration is expected to approve KarXT, the first new type of drug for schizophrenia in decades. It appears to be effective, but its main advantage is milder side effects.
The FDA has approved KarXT, the first new type of drug for schizophrenia in decades. It appears to be effective, but its main advantage over current treatments is milder side effects.